PureTech Health plc (LON:PRTC)
117.00
+0.60 (0.52%)
Sep 5, 2025, 4:39 PM BST
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
83.30K GBP
Profits / Employee
660.53K GBP
Market Cap
282.34M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56 | -34 | -37.78% |
Dec 31, 2023 | 90 | -21 | -18.92% |
Dec 31, 2022 | 111 | 16 | 16.84% |
Dec 31, 2021 | 95 | -155 | -62.00% |
Dec 31, 2020 | 250 | -50 | -16.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
PureTech Health News
- 10 days ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 10 days ago - PureTech Health plc reports 1H results - Seeking Alpha
- 10 days ago - Earnings Scheduled For August 28, 2025 - Benzinga
- 10 days ago - PureTech Health plc – Half-Year Report - Business Wire
- 17 days ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 20 days ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 25 days ago - PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint - Business Wire
- 26 days ago - PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases - Business Wire